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91. Introduction 
 
1.1 A case history 
E. was born in 1996 as a son of healthy non-related parents. Shortly after birth he developed 
symptoms of heart failure and a large perimembraneous ventricular septal defect (VSD) was 
found. With conventional heart failure medication (ACE-inhibitor, furosemide and digoxin) 
he did well until his VSD was closed surgically at the age of 24 months. He recovered 
quickly and there was no indication of any residual defect. Postoperatively slightly elevated 
pulmonary arterial pressure was normalized a few months later. Clinical follow-up was 
terminated 15 months after defect closure and the boy’s parents were informed that their son 
now was healthy. 
For more than a decade the boy developed normally without cardiac symptoms. In summer 
2009 he suddenly complained about exercise intolerance with breathlessness and dizziness 
during soccer training and matches. After several months of medical investigation by his 
family practitioner he was referred to a pediatric cardiologist. Cardiac examination revealed 
elevated right ventricular pressure at rest without right ventricular outflow tract obstruction. 
Based on these findings pulmonary arterial hypertension (PAH) was suspected and the 
patient was referred to Oslo University Hospital Rikshospitalet for further investigation. 
Clinical examination was without abnormal findings, the electrocardiogram (ECG) showed 
signs of right ventricular strain. Spirometry and CT scan of the lungs were normal. During 
cardiopulmonary exercise testing on a treadmill the boy had a maximal oxygen uptake of 
only 40% of expected aerobic capacity in a boy of his age. Echocardiography demonstrated 
no residual VSD. A velocity exceeding 4 m/s in the tricuspid valve regurgitation jet 
indicated a systolic pressure of at least 70 mmHg in the pulmonary artery. Right heart 
catheterization confirmed pulmonary hypertension with almost systemic pressure level in 
the pulmonary arterial system and with minimal effect of inhaled nitric oxide or 100% 
oxygen. Genetical analysis of the boy’s BMPR-2 gene by DNA sequencing and by 
multiplex ligation-dependent probe amplification (see chapter 3.10) revealed no mutation or 
insertion/deletion of the gene. Medication of his PAH has recently been established. 
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1.2 Growing up with congenital heart disease 
Advances in cardiac surgery and improved survival during the last few decades have created 
a new and rapidly increasing patient group for adult cardiology services to deal with: 
adolescents and adult patients with congenital heart disease of varying complexity and often 
with a history of multiple previous surgical interventions (1). Common synonyms for these 
patients are GUCH (“grown-up with congenital heart disease”) and ACHD (“adult with 
congenital heart disease”). Major concerns of clinical medicine and research are quality of 
life and long-term preservation of physical fitness in these patients as they often have 
residual defects or circulatory problems due to palliative surgery.  
1.2.1 Exercise capacity in congenital heart disease 
Exercise capacity in adult patients with congenital heart disease in general is reduced and it 
declines by age almost independently of the character of the initial defect (2;3). The causes 
and mechanisms of reduced exercise performance in these patients are not well understood. 
This patient group is heterogeneous in terms of cardiac anatomy and function which makes 
it difficult to identify and study single elements of cardiac and circulatory function that 
could cause impaired exercise performance. Strong and valid tools to assess left ventricular 
performance non-invasively by Doppler echocardiography have been developed for use in 
conventional cardiology and structural normal hearts. However, the right ventricle and the 
pulmonary circulation are regularly and strongly affected by various congenital heart 
defects. These parts of the heart and the circulation are far more difficult to assess reliably 
by ultrasound techniques. Therefore our knowledge about functional limitations of the right 
heart and the pulmonary circulation in congenital heart disease is still incomplete. 
1.2.2 The understanding of congenital heart disease 
The genetical background of congenital heart disease is almost undisclosed compared to our 
present genetical understanding of i.e. inborn errors of metabolism. Only a few genetical 
syndromes like trisomy 21 or 22q11-deletion syndrome have related heart malformations 
caused by a known genetical change. All other congenital heart malformations are caused 
by genetics which we do not know yet. It would be naive to believe that genetical changes 
could disturb cell migration during cardiac development leading to different macroscopic 
malformations without affecting microscopic structures and cellular function. Thus, 
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repairing the macroscopic structure does not repair the microscopic and functional changes 
in the congenital malformed heart. These changes continue to affect cardiac and circulatory 
function after macroscopic defect repair. Therefore it is crucial to achieve an understanding 
of congenital heart disease as a condition affecting all levels of the circulatory system from 
macroscopic structures like valves and vessels down to cellular function and intracellular 
regulatory mechanisms. 
1.3 Heart septal defects 
Ventricular septal defect and atrial septal defect (ASD) are the second and third most 
frequent congenital heart defects second after bicuspid aortic valve (4;5). Approximately 
two/one individuals out of 1000 live births have a VSD/ASD that will not close 
spontaneously later on. By current clinical practice surgical or catheter-based defect closure 
is performed in 22% and 67% of cases with non spontaneously closed VSD or ASD 
respectively (4). Thus, late morbidity related to the heart defect itself or to defect closure is 
a clinical issue concerning a great number of patients. 
The left-to-right shunt of blood flow in ASD and VSD, and eventually the pressure 
equalisation between the heart chambers in a large VSD, may lead to volume overload or 
combined pressure and volume overload in the pulmonary vascular system respectively. 
Pressure and volume cause endothelial stretch that in turn leads to pulmonary vasculopathy 
and eventually results in PAH (6). Defect closure has been performed in those septal defects 
assumed hemodynamically significant in order to prevent pulmonary vasculopathy and 
subsequent PAH. However, occurrence of PAH has been reported in patients with small 
open septal defects as well as many years after surgical defect closure, even without 
indications of perioperative PAH (7). The European Heart Survey on Congenital Heart 
Disease reported a prevalence of secondary PAH to be 18% in closed ASD and 26% in 
closed VSD (8), mainly from specialized centres. The material consisted of adult patients 
with late corrective surgery in the 60’s, 70’s and early 80’s compared to current surgical 
standards. The worrying results of the Euro Heart Survey were presented in 2004. The high 
prevalence of PAH in this data motivated us to perform this population-based study.   
To our knowledge, no data have been presented on the prevalence of PAH in patients with 
single ASD or VSD with access to cardiac surgery early in life. Otterstad et al published 
data from a partly invasive study on pulmonary arterial pressure at rest and during mild 
exercise in adult patients with isolated VSD almost three decades ago (9;10). The authors 
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demonstrated both reduced exercise performance and a high percentage of abnormal 
pulmonary arterial pressure response to exercise in their patients. However, none of the 
patients with surgically closed had been operated before 10 years of age which makes it 
difficult to compare their results directly to current patients with VSD and early surgical 
intervention. A better long-term prognosis in terms of lower prevalence of PAH has to be 
hypothesised when the defect has been closed within the first few years of life as in most 
cases today. 
1.4 Pulmonary arterial hypertension 
1.4.1 Definition and classification 
PAH has been in particular focus for research for the last twenty years. Major advances 
have been made in molecular pathobiology and in therapy of PAH. But still there is no 
generally accepted hemodynamic definition of PAH (11). Several international consensus 
conferences have suggested and revised the commonly used definition criteria for PAH. The 
latest revision was made in 2008 on the 4th World Symposium on Pulmonary Hypertension 
in Dana Point, CA (12). PAH is defined by mean pulmonary arterial pressure (mPAP)  25 
mmHg at rest in the presence of a pulmonary capillary wedge pressure  15 mmHg 
indicating normal pressure conditions in the left atrium. Remarkably the previous criteria for 
PAH during exercise was removed in the latest revision because of data indicating higher 
upper normal limits of mPAP during exercise in individuals older than 50 years (12). 
Likewise pulmonary vascular resistance (PVR) measured invasively is no longer suitable to 
define PAH in contrast to older definitions. 
The clinical definition and diagnosis of PAH has been dependent exclusively on invasive 
pressure measurement during right heart catheterisation. The development of Doppler 
echocardiography has become a tempting non-invasive alternative in clinical diagnostics. 
Comparative studies have shown that echocardiography underestimates pulmonary arterial 
pressure compared to invasive techniques especially in the presence of high pulmonary 
pressure (13). Upper normal limits of systolic pulmonary arterial pressure (sPAP) at rest 
assessed by echocardiography have been defined (14). The upper normal limit of sPAP 
during exercise is less well documented. Exercise studies in healthy individuals indicate that 
endurance trained athletes with high cardiac output may show pulmonary pressure 
conditions during exercise exceeding any definition of normal upper limit (15). Despite 
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methodological weaknesses Doppler echocardiography remains the best available clinical 
screening tool in detecting PAH (12;16). 
The latest international classification of pulmonary hypertension was published in 2009 
based on the consensus from the 4th World Symposium on Pulmonary Hypertension (17). 
Updated clinical classification of pulmonary hypertension (Dana Point, 2008): 
1. Pulmonary arterial hypertension (PAH) 
  1.1. Idiopathic PAH 
  1.2. Heritable 
   1.2.1. BMPR-2 
   1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
   1.2.3. Unknown 
  1.3. Drug- and toxin-induced 
  1.4. Associated with 
   1.4.1. Connective tissue diseases 
   1.4.2. HIV infection 
   1.4.3. Portal hypertension 
   1.4.4. Congenital heart diseases 
   1.4.5. Schistosomiasis 
   1.4.6. Chronic hemolytic anemia 
  1.5 Persistent pulmonary hypertension of the newborn 
  1.6 Pulmonary veno-occlusive disease and/or pulmonary capillary  
        hemangiomatosis 
2. Pulmonary hypertension owing to left heart disease 
  2.1. Systolic dysfunction 
  2.2. Diastolic dysfunction 
  2.3. Valvular disease 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
  3.1. Chronic obstructive pulmonary disease 
  3.2. Interstitial lung disease 
  3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
  3.4. Sleep-disordered breathing 
  3.5. Alveolar hypoventilation disorders 
  3.6. Chronic exposure to high altitude 
  3.7. Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
  5.1. Hematologic disorders: myeloproliferative disorders, splenectomy 
  5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis:      
         lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
  5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
  5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis 
The present project deals with the entity of PAH (PAH-classification category 1), where the 
pathogenesis is located on the arterial side of the pulmonary vascular bed caused by 
congenital heart disease (PAH-classification category 1.4.4). The classification has been and 
will be revised due to improving insight into pathogenesis and intrinsic factors of 
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susceptibility to PAH. In the future it may lead to further differentiation of PAH forms or 
fusion of different forms with common genetic and pathobiological background yet to 
discover. The 2008 classification suggest a novel subclassification of PAH secondary to 
congenital heart disease (category 1.4.4) into (17): 
A: Eisenmenger syndrome 
B: PAH associated with systemic-to-pulmonary shunts 
C: PAH with small defects 
D: PAH after corrective cardiac surgery 
1.4.2 Pathobiology 
Different forms of PAH show a similar molecular and histopathological development of 
vasculopathy (18;19). In the earliest stage of PAH there are only functional changes with 
failure of the pulmonary arterioles to dilate. Later in the pathogenetic process increasing 
muscularisation and wall thickening of the distal arterioles increase pulmonary vascular 
resistance. Subsequent hyperplasia of intima, media and adventitia leads to vessel occlusion. 
In the end stage of the disease one can find so-called plexiform lesions, a product of 
uncontrolled growth of all layers of the arteriolar wall into nodules of chaotic tissue 
arrangement. It is known that the pulmonal vascular endothelium plays a key role in the 
pathogenesis. However, the complex interaction between different cell types, signalling 
pathways, genetic changes and external damaging factors in the pathogenesis of PAH are 
still incompletely understood. 
Several biomarkers are connected to the cellular and molecular pathobiology of PAH. As an 
important component of the extracellular matrix, fibronectin is known to contribute in cell 
adhesion, migration, transformation and motility. It modulates phenotype and growth of 
vascular smooth muscle cells (20). A mechanism for translating cyclic stretch of the 
vascular smooth muscle cells into increased fibronectin production has been demonstrated 
in rats (21). In congenital systemic to pulmonary shunts, the migration from media to intima 
of vascular smooth muscle cells in pulmonary microvessels during pulmonary hyperflow is 
thought to be driven by a fibronectin gradient (22). Although measured in the circulation 
and not in the lungs, a higher serum level in patients with pathological pulmonary artery 
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pressure response during exercise could indicate that the demonstrated abnormal pressure 
response represents an ongoing vascular remodelling process. 
Von Willebrand factor is a marker of endothelial activation. Patients with serious pulmonary 
hypertension due to congenital heart disease are known to have alterations in von 
Willebrand factor function (23). A great number of other biomarkers and signalling 
substances have been investigated and related to different forms of PAH. An increased level 
of von Willebrand factor in the patients with operated, and thus hemodynamically 
significant, defects may indicate that these patients show a lasting state of endothelial 
activation.  
The whole aspect of current pathobiological understanding is too complicated to be 
presented or discussed in this context (24-26). 
1.4.3 Genetics 
The transforming growth factor-beta (TGF-beta) signalling pathway is crucial in both 
functional and structural changes in PAH (27). The majority of genes, that have been 
identified over the last decade and that are associated with different forms of PAH, are 
coding proteins of the TGF-beta superfamily: 
 Bone morphogenetic protein receptor type 2 (BMPR-2) is part of a membrane 
receptor interfering with cellular hyperplasia and apoptosis. The gene has been 
identified ten years ago (28-30). BMPR-2 mutations have been found in hereditary 
PAH in 70% of cases and in idiopathic PAH in 20% of cases (31-34). The 
prevalence of BMPR2-mutations in the  healthy general population is estimated to 
be approximately 0.01-0,001% (35). 
 Activin-like kinase-type 1 (ALK1) and  
 Endoglin (ENG) are two TGF-beta proteins associated with a rare form of PAH. 
Mutations in the ALK1 and the ENG gene have been demonstrated in cases of 
secondary PAH in hereditary hemorrhagic teleangiectasia (HHT) (36;37). 
Interestingly proteins of the transforming growth factor- (TGF-) signalling pathway have 
also been shown to be important prenatally in cardiac and pulmonary vascular development 
(38-41). Bone morphogenetic protein type 2 (BMP2) is crucial in coordinating multiple 
aspects of atrioventricular canal morphogenesis (42) and cardiac looping (43). This genetic 
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connection between PAH pathogenesis and cardiac and pulmonary vascular embryology 
made genetic changes in the TGF-beta superfamily a key issue to investigate in our study. 
 
1.4.4 Exercise-induced pulmonary arterial hypertension 
Exercise-induced PAH or abnormal right ventricular systolic pressure response is an 
incompletely understood phenomenon and its clinical significance is still uncertain (44). 
Possible pathophysiological mechanisms behind excessive pressure rise in the pulmonary 
vascular system during exercise include fixed structural changes in the pulmonary 
vasculature, pulmonary arteriolar vasoconstriction or disturbances in left ventricular 
diastolic or systolic function. In patients with congenital heart disease, post-surgical 
alterations in contractility like dyssynchrony caused by left bundle branch block may 
contribute to a backward failure resulting in exercise-induced PAH (45). 
Exercise-induced PAH is a marker of early pulmonary vasculopathy in hereditary PAH and 
in PAH associated with scleroderma in individuals who will develop PAH at rest later in life 
(44;46;47). Exercise-induced PAH or abnormal right ventricular systolic pressure response 
(RVPR) during sea level exercise and RVPR due to hypoxia has been shown to correlate 
closely. Both methods can identify individuals susceptible to high altitude pulmonary 
oedema (48-50) which demonstrates the common pathophysiological vasoconstrictive 
nature of  hypoxic PAH and exercise-induced PAH. 
The pathogenesis of PAH beginning with functional disturbances progressing into structural 
changes gives rise to the hypothesis of exercise-induced PAH as an early stage of disease in 
any form of PAH. However, this progression from early exercise-induced PAH into PAH at 
rest has to be demonstrated in a longitudinal approach for each of the different etiological 
forms of PAH like PAH secondary to congenital heart disease with left-to-right shunt.
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2. Aims of the study 
2.1 Exploration of methods and normal limits 
We aimed to define the normal range, in particular the upper normal limit, of right 
ventricular systolic pressure (RVSP) in adolescents and young adults during exercise, as 
measured by non-invasive ultrasonic techniques. We aimed to investigate the interrelation 
of RVSP to the aerobic exercise capacity, and to establish whether endurance-trained 
athletes differ from the normally trained population. 
2.2 Prevalence of exercise-induced PAH 
In this main part of our study we wanted to investigate right ventricular pressure response 
(RVPR) to exercise and its interrelation to aerobic capacity and to right ventricular (RV) 
performance. We aimed to test our hypothesis that exercise-induced would be found more 
often in patients with large defects, late defect closure and more often in VSD than ASD. 
2.3 Characterising the condition: dynamic versus static 
The altitude study aimed to explore to what extent abnormal RVPR in patients with 
surgically closed ASD or VSD is a dynamic condition which can be influenced by external 
factors like hypobaric hypoxia during simulated moderate altitude conditions. We wanted to 
investigate if abnormal RVPR can be evoked by moderate altitude or if abnormal response 
at sea level can be worsened by moderate altitude. We were interested whether altitude-
induced changes likewise would be more pronounced in patients with VSD as compared to 
patients with ASD who had shown lower prevalence of exercise-induced PAH (51). 
2.4 Genetical susceptibility 
Finally we aimed to investigate the relationship between exercise-induced PAH in our group 
of patients and genetic changes related to the TGF- signalling pathway. 
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3. Material and methods 
 
3.1 General methodological considerations 
Careful consideration of examination methods is necessary for investigation of pulmonary 
circulation. Non-invasive techniques like echocardiography and cardio-pulmonary exercise 
testing are preferable by ethical considerations and they are relatively inexpensive. Invasive 
measurements during right heart catheterisation are more precise and reliable but by today’s 
clinical resources and ethical standards they are almost impossible to achieve in large study 
groups of patients and healthy controls. 
Non-invasive techniques permit examination of numerous individuals without the need of 
invasive heart catheterisation. Ultrasound measurements reliably assess many structural and 
functional parameters inside the heart and the great vessels. In almost every 
echocardiographic measurement there is a varying degree of observer dependent variability 
and accuracy. Both over- and underestimation are relevant issues. I.e. the overestimation of 
pressure gradients by Doppler techniques compared to catheter-based measurements is well 
known. Thus, the researcher, who wants to investigate a hemodynamic phenomenon like 
exercise-induced PAH, has to face technical limitations and questions about data quality. As 
the aim of the study was to investigate the prevalence and character of exercise-induced 
PAH in a large group of patients and healthy controls we had to choose a non-invasive 
approach. 
Exercise echocardiography had its first breakthrough in research during the 1980’s. Several 
issues were studied by this practical challenging technique: contractility in heart failure or 
coronary vessel disease and pressure gradients in valve disease were the main fields of 
investigation. As the use of pharmacological stress during echocardiography became more 
widespread, the need to compromise with poor image quality and exercise derived artefacts 
was less attractive. 
The ability of exercise echocardiography to detect exercise-induced PAH has been 
demonstrated in patients with scleroderma (47), in individuals with a genetic risk of PAH 
(46;52) and in healthy individuals susceptible to high altitude pulmonary oedema (53). 
Exercise echocardiography has also been performed in small patient groups with congenital 
heart disease (54-57). 
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Echocardiography has been shown to give reliable measurements of RVSP compared to 
invasive measurement at rest (58) and during exercise (54;59).  In the absence of right 
ventricular outflow tract obstruction, RVSP reflects pulmonary arterial pressure (60-62). 
Previous studies have demonstrated the relationship between systolic and mean pulmonary 
arterial pressure (63;64) which by consensus defines the diagnosis of PAH (65).  
3.2 Patient group 
In the Norwegian regions of Vestfold, Asker and Bærum, 72 children were born between 
1982 and 1993 with isolated VSD or ASD and without right ventricular outflow tract 
obstruction (RVOTO). This count did not include patients with spontaneously closed 
foramen ovale or VSD during follow-up and patients with complicating conditions 
preventing appropriate exercise testing (i.e. trisomy 21). The 72 patients had at the time of 
inclusion either an open defect or they had undergone defect closure. Two individuals with 
device-closed ASD were excluded to prevent device related confounding. Three patients 
with surgical closed VSD were excluded because of abnormal rise in right ventricular 
outflow tract velocities above 2.0 m/sec during exercise indicating dynamic RVOTO. Of 67 
eligible patients 23 were lost to follow-up (6 patients) or refused participation (17 patients). 
Among these 23 were 18 patients with VSD and 5 patients with ASD. As these patients 
were not examined in our study there might have been several cases of spontaneous defect 
closure after the latest cardiac examination report in their medical record. The patients who 
were lost to follow-up had either changed their home address and could not be identified in 
official registries, or did not answer our invitation, or did not meet to any of maximal two 
clinical appointments. The reasons for refusing participation varied from lack of time, 
participation in other clinical studies, and to unwillingness to be interviewed and examined 
in a setting related to their heart condition. We had no indications that there were any cases 
of current cardiac problems or complications involved in those 23 eligible cases that did not 
participate. 
Finally 44 patients could be included in the study. All patients with ASD had a surgically 
closed defect, 3 by patch closure and 14 by direct suture. Eleven patients had their VSD 
closed surgically, 7 by direct suture and 4 by patch closure. Two of these (18%) had minor 
residual shunts. No patient received specific treatment of PAH before or after surgery; 
however, preoperative catherization data were available only in a few patients. Velocity 
measurements across the ventricular septum in 16 patients with untreated small muscular or 
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small perimembraneous VSD (4.5±0.51 m/s) indicated normal RV pressure at rest. Two 
defects were identified by color-Doppler mapping but were too small for velocity 
assessment. For basic patients group characteristics see paper II, table 1.
3.3 Control group
The patient group was matched individually 2:1 against 88 healthy control subjects of the 
same sex and age (+/- 12 months). The healthy control subjects were recruited among 
hospital employees and their relatives, among college students and among other local 
citizens volunteering subsequent to newspaper articles. The volunteers had no known heart 
or lung disease; however mild bronchial asthma was accepted. For basic control group 
characteristics see paper II, table 1. 
3.4 Clinical examination 
All patients and healthy members of the control group were examined including 
auscultation of the heart and lungs, measuring of resting blood pressure and obtaining an 
electrocardiogram (ECG). A medical family history and construction of a pedigree was part 
of the standard interview.
3.5 Exercise testing 
All patients and control subjects were examined by cardiovascular exercise testing on a 
treadmill ergometer with gas exchange analysis and ECG following the Oslo protocol (66) 
(Equipment: Jaeger Oxycon Delta, VIASYS Healthcare GmbH, Höchberg, Germany). Peak 
oxygen uptake (VO2peak) was corrected for body weight (67) and expressed as ml/kg-0.67min-
1. The individual results were compared to reference values from healthy Norwegian 
adolescents (68) and expressed by standard deviation (Z-score) from age-related mean in the 
reference material. Highly endurance-trained volunteers with a Z-score > 2 were excluded 
from the study because of the known phenomenon of elevated pulmonary arterial pressure 
levels in athletes (15;69). One patient’s treadmill exercise was considered submaximal and 
consequently excluded from further analysis. 
We chose to perform a maximal cardiopulmonary exercise test before exercise 
echocardiography even if this order of tests could reduce pulmonary vascular resistance and 
lead to falsely low exercise-induced RVSP values. We tried to minimise the effect by 
having a resting phase of one hour between treadmill exercise and supine cycling during 
exercise echocardiography.  The alternative of performing the tests on different days would 
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have been a difficult task for most participants who mainly had educational obligations as 
students. Measurement of oxygen consumption during supine cycling as a second 
alternative would have lead to falsely low VO2peak results (70). 
3.6 Echocardiography at rest 
Echocardiographic recordings were obtained with a Vivid 7 scanner (GE Vingmed 
Ultrasound, Horten, Norway). All echocardiographic studies were videotaped and saved 
digitally (still frame and loops). Right atrial pressure at rest was estimated by vena cava 
inferior index (71). RV performance (72-74) was measured by M-mode registration of 
tricuspid annular plane systolic excursion (TAPSE) (75) and peak tricuspid annular plane 
systolic motion velocity (TASM) measured by colour tissue Doppler (76;77). 
3.7 Exercise echocardiography 
One hour after treadmill testing, exercise echocardiography was performed during supine 
cycling with about 30 degrees elevation and left side tilt (Equipment: Ergoselect 1200 EL, 
Ergoline GmbH, Bitz, Germany). A stepwise exercise protocol was used with a starting load 
of 25 Watt and an increase of 25 Watt every second minute until the target heart rate of 160-
min was reached. Above that level, echocardiographic recordings become futile because of 
upper body movement and interposition of the lungs. Systemic blood pressure was 
measured at every exercise level, as well as the maximal velocity of tricuspid regurgitation 
jet. The right ventricular systolic pressure (RVSP) was calculated from each recording by 
means of the modified Bernoulli’s equation, adding the right atrial pressure at rest to the 
calculated pressure gradient between RV and right atrium (58). In order to detect dynamic 
RV outflow tract obstruction that could interfere with RVSP measurements, RV outflow 
tract velocity was measured at the 100 Watt level. Patients with outflow tract velocities 
higher than 2 meters per second were not included in the study. 
3.8 Altitude simulation 
The selected patients for the altitude study were examined by ExE during supine cycling at 
sea level right before exposition to altitude conditions. Using a hypobaric chamber the 
patients then were exposed to a simulated ascent to an altitude of 2500 meters or 8200 feet 
above sea level. During the following two hours of supine rest (altitude adaptation phase) 
peripheral oxygen saturation (SpO2), blood pressure, RV performance and RVSP were 
monitored every 15 minutes. Finally ExE was repeated before descent. 
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All altitude tests were conducted in a hypobaric chamber (Norwegian Universal Technology 
AS, Haugesund, Norway). After decompression atmospheric conditions were monitored 
every five minutes. During altitude adaptation and altitude exercise the air temperature was 
21.5±1.2 ºC. Chamber pressure after decompression simulated a stable altitude of 2500 
meters, oxygen percentage was 20.8±0.04 % and carbon dioxide percentage was 
0.044±0.013 %. 
3.9 Biochemical analysis 
Blood samples were taken of all patients prior to exercise for biochemical analysis. 
Concentration of haemoglobin, sodium, potassium and N-terminal pro brain natriuretic 
peptide (pro-BNP, kit Modular E by Roche Diagnostics AS, Oslo, Norway) were assessed. 
Fibronectin was measured by EIA using antibodies from DakoCytomation (Denmark). EIAs 
for CRP, vWf, IL-8, sTNFR1, TNF, MCP-1, RANTES, OPG and CD40-ligand.were 
performed as formerly described (78). Briefly, 96 well plates were coated overnight at 4ºC 
with 100 uL rabbit anti-human antibody at 10 mg/L in PBS. 0.1% Tween 20 in PBS was 
used as a buffer in subsequent steps. Standard was pooled serum diluted 1:100 – 1:6400. 
After blocking samples, 100 uL standard or diluted samples (1:1600) were added and 
incubated at 37C for 2 hours. The plate was washed and 100 uL peroxidase-conjugated 
rabbit anti-human antibody was added (1:4000) and incubated 37C for 1 hour. Plates were 
developed with tetramethylbenzadine (Zymed Laboratories Inc., Germany), stopped with 
H2SO4, and read at 450 nm. All samples from the same individual were run on the same 
plate to avoid run-to-run variation. All patients with abnormal RVPR had VSD (Paper II). 
We therefore analyzed for differences between those surgically treated and those not, due to 
the fact that surgical intervention is an indicator of former hemodynamic significance of the 
lesion. 
3.10 Genetical analysis 
Screening for mutations in the BMPR-2 gene (GenBank accession number Z48923.1) was 
performed by DNA sequencing to detect point mutations and small insertions/deletions 
within exons and the flanking intron sequences, and by multiplex ligation-dependent probe 
amplification (MLPA) to detect structural alterations. For DNA sequencing, DNA was 
extracted from EDTA-containing blood by the use of a BioRobot EZ1 (Qiagen GmbH, 
Hilden, Germany). Individual exons with flanking intron sequences were amplified by PCR. 
Typically, approximately 50 base pairs of flanking intron sequences were included in the 
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amplicons. The primer sequences and conditions for the thermal cyclings are available upon 
request. Standard DNA sequencing reactions using version 3.1 of Big Dye terminator cycle 
sequencing kit (Applied Biosystems Inc., Foster City, CA) were analysed on a Genetic 
Analyzer 3730 (Applied Biosystems Inc., Foster City, CA). The software prediction 
program PolyPhen (www.bork.embl-heidelberg.de/PolyPhen/) was used to assess the 
pathogenicity of identified missense mutations. For MLPA analysis, DNA was extracted 
from EDTA-containing white blood lymphocytes by the manufacturer’s protocol, on a 
Magnapure DNA Extractor (Roche Diagnostics GmbH, Mannheim, Germany). The SALSA 
MLPA kit P093 HHT/PPHT1 (MCR-Holland, Amsterdam, The Netherlands) was used to 
test for deletions or duplication in the BMRP-2 gene, the ENG gene and the ALK1 gene. 
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4. Summary of results 
 
4.1 Paper I and related results 
Our data has shown a great variability in right ventricular pressure response to exercise. 
There is no linear correlation between maximal right ventricular systolic pressure and 
aerobic capacity, but athletes with high aerobic capacity often show an abnormally high 
RVPR. The upper normal limit of the RVPR in normally trained individuals seems to be 50 
mmHg RVSP which is higher than commonly assumed (79). 
Athletes show a continuous rise in RVSP without ever reaching a plateau even during high 
workload levels presumably due to extremely high cardiac output as shown in previous 
studies (15;69;80). As both normal and abnormal RVSP responders in our study reach a 
RVSP plateau during exercise one would assume different mechanisms leading to high 
RVSP pressure during exercise in these patients and in highly trained athletes. 
4.1.1 Inter-observer agreement and variability of exercise echocardiography 
For analysis of inter-observer variability a blinded second analyzer evaluated 35 ExE 
recordings (18 patients, 17 controls). The second analyzer was experienced in ExE 
technique. Inter-observer agreement was expressed by a Bland-Altman-plot (81).
 
Figure 1: Bland-Altman-Plot of inter-observer variability in tricuspid regurgitation jet 
velocity measurements 
25
The two independent observer’s analysis showed very good agreement. The 95 % limits of 
agreement were -0.17/0.33 meters per second with a positive bias of only 0.06 meters per 
second in Doppler velocity measurements (figure 1) and only 2 mmHg in maximal RVSP 
between first and second analyzer. There was no difference in agreement depending on low 
or high velocities. For tricuspid regurgitation velocities measured offline by the two 
observers, the intraclass correlation coefficient was 0.93 (p<0.001). Inter-observer 
agreement was possible to measure by Kappa statistics in order to define abnormal pressure 
response to exercise. With a cut-off at 50 mmHg RVSP, Kappa was 0.82. Our study results 
from inter-observer agreement have not been published elsewhere. 
 
4.2 Paper II and related results 
4.2.1 Aerobic exercise capacity and RV performance 
Aerobic exercise capacity expressed by Z-score of VO2peak in the patient group and 
subgroups were significantly lower compared to the control group (paper II, table 2, figure 
4). There was no difference in aerobic capacity between any of the different patient groups 
(ASD, all VSD, open VSD, closed VSD). Z-score of VO2peak correlated inversely to age at 
defect closure for VSD but not for ASD. The patients who had undergone surgical defect 
closure had significantly reduced RV performance with no difference between closed ASD 
and closed VSD (paper II, table 2, figure 5). 
4.2.2 Exercise-induced pulmonary hypertension 
There was no case of pulmonary hypertension at rest (RVSP > 40 mmHg) and no difference 
in RVSP at rest between patients and control group. Exercise echocardiography permitted 
assessable measurements of RVSP by tricuspid regurgitation jet velocity in 85 controls (97 
%) and in all patients. The difference between the patient group and the control group 
during exercise was not evident in the group mean of maximal RVSP (paper II, table 2, 
figure 6) but in pressure rise pattern (paper II, figure 1) and in the frequency of abnormal 
RVSP response (paper II, table 3). There was a higher rise angle in RVSP during the first 
minutes of incremental workload in the patient group compared to the control group 
(p=0.007). The number of subjects with RVSP response > 50 mmHg was significantly 
higher in both VSD groups compared to the ASD group (p=0.044 in open VSD versus ASD, 
p=0.005 in closed VSD versus ASD). There was no difference in the occurrence of 
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abnormal RVSP response > 50 mmHg between patients with untreated small restrictive 
VSD and surgically closed VSD (4/16 and 5/11 respectively) and no relationship between 
abnormal RVSP response and residual VSD after surgery. However, in contrast to the 
subgroup with closed VSD the higher frequency of abnormal RVSP response within the 
subgroup of patients with untreated small VSD compared to the matched control subgroup 
did not reach statistical significance (paper II, table 3). The curve angle of RVSP rise in 
patients with RVPR > 50 mmHg was steeper than in other patients (p<0.001) (paper II, 
figure 2). Normal and abnormal RVSP responders reached a RVSP plateau at different 
pressure levels. Systolic blood pressure rise during the first minutes of exercise showed no 
difference in curve angle in patients with normal or abnormal RVPR (paper II, figure 3). 
4.2.3 Intracardiac dyssynchrony / QRS-prolongation 
Resting electrocardiogram showed no significant difference in occurrence of QRS 
prolongation among patients (3/44, 7%, all post surgery VSD) and controls (2/88, 2%). 
There was a significant correlation between QRS prolongation in the resting 
electrocardiogram and abnormal RVPR above 50 mmHg for the control group (QRS 
prolongation in 1/4 abnormal responders, p=0.002) but not for the patient group (QRS 
prolongation in 1/9 abnormal responders). 
4.2.4 Results of biochemical analysis 
All standard measurements of haemoglobin, sodium, potassium were within normal range 
and without relationship to RVPR or aerobic exercise capacity. Pro-BNP was measured in 
42 patients. Two patients had pro-BNP values above the upper normal limit of 20 pmol/L 
(24 and 31 pmol/L respectively). No significant correlation was found between pro-BNP 
exceeding 20 pmol/L and abnormal RVPR. 
For the whole patient group (n=38 with available s-fibronectin data), a weak connection was 
found between maximal right ventricular pressure during exercise and serum fibronectin 
levels (Spearman’s Rho = 0.28, p=0.095) (figure 2). The group of patients with maximal 
RVSP > 50mmHg (n=8) showed a tendency towards a higher serum fibronectin level than 
in patients with maximal RVSP  50mmHg (mean 180 mol/mL [112, 248] versus 127 
mol/mL [105, 151], p=0.056) (figure 3). Patients operated for VSD had higher von 
Willebrand factor than those not operated (123 mol/mL [91,156] versus 87 mol/mL 
[66,109], p=0.03) (n=23 with available von Willebrand factor data). 
 
 
Figure 2: scatterplot of s-fibronectin 
versus maximal RVSP during exercise. 
 
  
 
Figure 3: boxplot of s-fibronectin in 30 
patients with RVSP response within 
normal limits as compared to 8 patients 
with abnormal RVSP response.
Results from biochemical analysis have not been published elsewhere. 
 
4.3 Paper III 
Moderate altitude increases oxygen desaturation during exercise and right ventricular 
systolic pressure at rest and during exercise in adolescents with ventricular or atrial septal 
defects. Oxygen desaturation during altitude exercise is more pronounced as compared with 
data from studies in healthy individuals (82-84). RVSP may increase by exposure to 
moderate altitude alone. Abnormal RVPR to exercise can be evoked by moderate altitude in 
individuals with normal RVPR at sea level. Abnormal RVPR to exercise at sea level can be 
aggravated by moderate altitude. Our study did not demonstrate any relationship between 
aerobic exercise capacity and changes in RVPR or oxygen 
 
4.4 Paper IV and related results 
We examined the same group of 44 subjects with isolated ASD or VSD as presented in 
paper I and paper II. Two patients with borderline or abnormal RVSP response to 
submaximal exercise were found to be heterozygous for mutation Y589C (c.1766, A>G) in 
exon 12 of the BMPR-2 gene and three were found to be heterozygous for mutation S775N 
(c. 2324, G>A) in exon 12 in the same gene. Analysis of the pathogenicity of two mutations 
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by the use of the prediction program PolyPhen, revealed that mutation Y589C was predicted 
to be “Probably damaging”, whereas S775N was predicted to be “Benign”. None of the 
subjects had deletions or duplication in the BMPR-2 gene, the ALK1 gene or the ENG gene. 
To our knowledge mutation Y589C in the BMPR-2 gene is a novel mutation predicted by 
PolyPhen to be pathogenic, whereas mutation S775N has been previously reported (85) and 
has also been found in healthy controls (86). 
4.4.1 Pedigree analysis 
For all included patients and control subjects a pedigree of three generations was obtained. 
Of all subjects there was only one family with multiple cases of congenital heart defect. It 
was the family of a 14 year old girl with a minor untreated VSD in the muscular septum. 
She had five siblings of which one had Tetralogy of Fallot and another was born with a 
muscular VSD that closed spontaneously during childhood. The girl from our study had a 
normal RVSP response during exercise and no detectable DNA mutation. 
None of the other 131 pedigrees showed any familial recurrence of congenital heart defect 
or individual medical histories indicating pulmonary hypertension. Pedigree results have not 
been part of any publication yet. 
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5. General discussion 
 
5.1 Aerobic exercise capacity 
The findings of reduced aerobic capacity in all patient groups confirm previous studies 
(2;3;54;55) though without any indication that abnormal pulmonary pressure response limits 
exercise capacity. Interestingly we can demonstrate a positive effect towards better exercise 
capacity when patients with VSD had their defect closed earlier. As this effect seems not to 
be related to pulmonary vasculopathy, it may be hypothesised that sternotomy in younger 
patients is tolerated better with a lower tendency to restrictive respiratory characteristics 
later in life (87). 
5.2 Exercise-induced pulmonary arterial hypertension 
Technically our non-invasive investigative approach studies systolic pressure conditions in 
the right ventricle at rest and during exercise. Hence some conclusions have to be based on 
previous data and study results like the possibility to estimate right atrial pressure which in 
addition is assumed nearly unchanged during submaximal exercise. We find the published 
data on this issue sufficient to allow conclusive RVSP measurements. 
Whether measurements of RVSP permit conclusions about pulmonary arterial pressure is 
another important discussion. The primary source of confounding to be excluded is, of 
course, any flow obstruction between the right ventricle and the pulmonary arterioles as we 
have tried to take in account in our study protocol. As PAH is defined by invasively 
measured parameters like mean pressure and PVR, one could argue that catheterisation 
would have been the only acceptable way to acquire information about exercise-induced 
PAH. In the light of ethical considerations and the documented validity and reliability of 
echocardiographic techniques, we think that our methods and results allow careful 
conclusions abnormal RVPR reflecting a pulmonary hypertensive phenomenon. 
As patients with closed ASD showed a RVSP response to exercise comparable to controls it 
seems that excessive pulmonary vascular flow without pressure overload is not enough to 
cause changes in pulmonary vascular endothelium. The patients with closed VSD showed 
significantly elevated RVPR as a group and a significantly higher rate of abnormal pressure 
responders. These findings could be interpreted in terms of exclusively pressure-related 
vasculopathy if not patients with unoperated minor VSD had shown the same pattern of 
30
pathological RVPR to exercise which is a surprising finding. Hypothetically the inadequate 
ventricular septation itself might be part of a cardiopulmonary vasculopathy that also affects 
the pulmonary endothelium. The common involvement of TGF-beta signalling in cardiac 
development, pulmonary vascular development and post-natal pathogenesis of PAH 
supports this hypothesis. Thus, our data may support the theory of multi-etiological PAH 
caused by a combination of external triggering factors like pulmonary vascular overload and 
intrinsic susceptibility that may include male sex and other genetical factors (88). 
Results from the altitude study demonstrate that exercise-induced PAH in our patient group 
can be affected by external conditions. This finding contradicts speculations that exercise-
induced PAH only reflects static structural changes in the pulmonary vasculature due to 
early excessive pulmonary blood flow. Our data merely suggests that exercise-induced PAH 
reflects a dynamic pulmonary vasoconstrictive mechanism which presumably involves the 
pulmonary vascular endothelium. This theory is also supported by our finding of elevated 
inflammation markers in patients with abnormal RVPR. 
5.3 Right ventricular performance 
Our data show that RV performance reduces in patients who have undergone cardiac 
surgery. Hypothetically the surgical incision of the pericardium and the right atrium, the 
mobilisation of the tricuspid valve apparatus, implantation of artificial patches, post-
operative inflammation and scarring are possible mechanisms that may influence on right 
ventricular contractility. Disturbances in the pulmonary circulation like exercise-induced 
PAH may represent an afterload stress of varying degree that also may reduce RV 
performance over time. Our data support the common view that RV function plays a key 
role in long-term functional outcome in congenital heart disease especially after corrective 
cardiac surgery. Improved techniques of visualisation and functional RV assessment 
hopefully will give answers to the question about nature of decreased RV performance. 
5.4 Clinical consequences 
As the average age at defect closure has decreased during the last 20 years, a lower 
prevalence of abnormal RVPR would be expected in patient populations treated according 
to modern surgical practice. However, our data could not demonstrate that age at surgery 
predicts abnormal RVPR later in life. The finding of abnormal RVPR in patients with small 
unoperated VSD is surprising and warrants further investigation, as these patients often are 
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outside follow-up programs. A comparable previous study has not demonstrated late 
presenting PAH in patients with small untreated VSD (89). 
Our findings raise some questions about the indications for surgical treatment, timing of the 
operation and follow-up, but the data do not allow for firm conclusions or guidelines. 
Further studies are needed in order to define the potential benefit and optimal timing of 
surgery, especially with respect to small defects. The natural course of abnormal RVPR 
during exercise is also unknown. In case it represents a dynamic condition with worsening 
by time, it may warrant follow-up and even medical treatment of these patients. As every 
second of the patients with closed VSD showed exercise-induced PAH it seems worth to 
consider life-long clinical follow-up in this group even if the immediate surgical result is 
good without residual defects. 
5.5 Future perspectives 
Due to this possible progression into PAH and in the light of the presented data one might 
consider screening of all VSD patients by exercise echocardiography in adolescence. In case 
of abnormal RVSP response the individual clinical follow-up should be continued life-long 
in all patients with treated or untreated open left-to-right shunt regardless defect size. 
Treatment of possible later PAH at rest then could be initiated before the debut of clinical 
symptoms which might improve the patients’ prognosis. 
Our genetical findings might just be early results in a rapidly expanding field of genetical 
research in congenital heart disease. One might speculate that the near future will bring 
genetical diagnostics into clinical and surgical decision-making. A patient with genetical 
determined susceptibility to PAH might be scheduled for earlier defect closure than a patient 
without a certain mutation. In the future some patients might even receive pulmonary 
vasodilative treatment in infancy waiting for surgical or catheter-based defect closure, if 
their genetical risk of pulmonary vasculopathy is high. 
5.6 Strength and limitations of the study 
The inclusion of patients to the study was population-based as there was no systematical 
difference between included and not-includable patients from the eligible proportion of all 
subjects born with isolated VSD or ASD. This strengthens our results and conclusions about 
the observations. A particular advantage was the ability to identify patients outside clinical 
follow-up with minor open VSD or with uncomplicated surgically closed defects without 
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residual defect. These groups are often ignored by publications about long-term morbidity in 
congenital heart disease as they are difficult to identify without good medical registries and 
a nationally coordinated public health care system. The mean age at surgical defect closure 
was somewhat higher in the late 80’s and early 90’s compared to current standard. Early 
surgical defect closure did not seem to influence or prevent later exercise-induced PAH at 
least in the presented study. In our opinion that makes the presented data applicable on 
today’s patient population even if cardiac surgery if performed earlier in life. 
In a simplified way, our study allows investigation of three subgroups of different overload 
situations in the pulmonary circulation that may cause damage in the pulmonary 
endothelium. Minor pulmonary vascular overload in patients with small open VSD assumed 
hemodynamically insignificant. These patients have a small transseptal high velocity jet 
which may affect hemodynamics and endothelial function. Isolated volume overload in 
patients with a closed ASD and finally combined volume and pressure overload in patients 
with a closed moderate or large VSD. The last 2 groups have a varying duration of 
pulmonary vascular shear stress until defect closure. As perioperative PAH was absent in 
patients with closed defects abnormal RVPR represents rather a closure independent 
condition than a vasoconstrictive residual after previous PAH. 
Our institutions’ medical records did unfortunately not allow differentiation of preoperative 
defects into moderate or large left-to-right shunt as there were no catheterisation data or 
chest X-ray available in every case. Thus, the hypothesis that the patients with the largest 
defects preoperatively would show the highest prevalence of exercise-induced PAH later in 
life could not be tested in our study. It is important to remember that the population-based 
distribution of defects in our material favouring small and moderate sized defects. 
The pro-and-contra of our non-invasive approach in this study has been addressed in section 
3.1. In our study we had to examine a large number of healthy young patients and an even 
larger number of healthy volunteers. This enabled us to draw general conclusions about 
prevalence of exercise-induced PAH in patients with VSD. By ethical, practical and 
financial reasons an invasive study design based on right heart catheterisation data would 
have been impossible to achieve. Thus, performing our investigative task meant to deal with 
the weaknesses of ultrasound technology. By doing a proper method evaluation and by 
exploring the limits of normality in RVPR as described in paper I, we wanted to minimise 
this methodological disadvantage. However, this research strategy could never give answers 
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about invasive hemodynamic characteristics like pulmonary vascular resistance which is 
often proposed as the gold standard of PAH diagnostics. The underlying hemodynamical 
mechanisms of exercise-induced PAH and their relation to i.e. intrapulmonary circulation or 
left heart dysfunction will be challenging to investigate even with invasive techniques.   
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6. Conclusions 
 
Exercise-induced pulmonary hypertension can be reliably assessed non-invasively by 
exercise echocardiography. Exercise-induced PAH has a high prevalence in healthy young 
patients with VSD. It can be found in patients who had their defect closed early in life, but 
also in patients with small VSD that are commonly considered hemodynamically benign. 
Thus, exercise-induced PAH seems to be caused not only by hemodynamic influence of 
shunt-related excessive blood flow to the pulmonary vascular system before the defect is 
closed. Our data suggest that mutations in the TGF-beta signalling pathway may play a role 
in the pathogenesis of exercise-induced PAH in congenital heart malformations in the same 
way as it has been shown to act in other forms of PAH. 
Our data indicate that exercise-induced PAH is not due to a fixed anatomic change in the 
patients’ pulmonary vascular bed. It seems rather to be a dynamic vasoconstrictive condition 
which can be evoked or aggravated by external factors like hypobaric hypoxia. This finding 
leads to the hypothesis that there might be a progression into PAH at rest as the patient gets 
older, at least in some cases. This hypothesis should be the subject of further investigation. 
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Abstract Introduction: Exercise echocardiography assesses exercise-induced pulmonary hypertension. The
upper normal limit of right ventricular systolic pressure during exercise is not well established. Our study
aims to investigate the response of right ventricular systolic pressure in relation to aerobic capacity. Methods
and results: Cardiopulmonary exercise testing using a treadmill, and echocardiography during supine cycling,
were performed in 113 healthy volunteers aged 13 to 25 years. Maximal right ventricular systolic pressure
during evaluable exercise studies obtained in 108 subjects showed a Gaussian distribution only after
separating the endurance trained subjects, specifically 12 athletes with Z-score of peak oxygen uptake higher
than 2.0, from the normally trained group of 97 subjects. Maximal right ventricular systolic pressure during
exercise in the normally trained group showed a mean of 38.0 millimetres of mercury, with standard deviation
of 7.2, a median value of 39.0, and a range from 17 to 63, and the 95th percentile was 51 millimetres of
mercury. In the athletes, the maximal right ventricular systolic pressure was higher, with a median of 55.5, a
range from 28 to 69, this being significant, with p equal to 0.004). Of the 12 athletes, 8 (67%) showed a
response of right ventricular systolic pressure to exercise exceeding 50 millimetres of mercury, but only 8 of 97
normally trained subjects (8%) showed a similar response, this also being significant, with p less than 0.001.
Conclusions: Our study confirms the great variability in the response of right ventricular systolic pressure to
exercise in healthy individuals, with 50 millimetres of mercury representing the upper normal limit. Endurance-
trained athletes show higher levels, and two-thirds have abnormal responses exceeding 50 millimetres of mercury.
Keywords: Exercise echocardiography; exercise physiology; pulmonary hypertension; pulmonary circulation
P
ULMONARY ARTERIAL SYSTOLIC PRESSURE, AND RIGHT
ventricular systolic pressure, are approximately
one-quarter of systemic arterial pressure, and
are considered to remain nearly unchanged during
exercise. Few studies, however, have investigated
normal pulmonary pressures during exercise.1–3
A known pulmonary arterial systolic pressure allows
calculation of the mean pulmonary arterial pressure,
which by consensus defines pulmonary arterial
hypertension.4,5 The use of invasive methods to
measure pulmonary arterial pressure in healthy
individuals is limited by ethical considerations.
Echocardiography has been shown to provide reliable
measurements compared to invasive measurement at
rest,6 and during exercise.7,8 In the absence of an
obstructed right ventricular outflow tract, the systolic
pressure reflects, but does not equal, pulmonary
arterial systolic pressure.2
International guidelines define the normal upper
limits of pulmonary arterial systolic pressure at rest,
but there is a general uncertainty about the upper
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limits for both pulmonary and right ventricular
systolic pressures during exercise.9,10 A value of
40 millimetres of mercury, or in some papers
45 millimetres of mercury, is proposed as the upper
normal limit during exercise.2,3,11 Recent studies,
however, have shown an abnormal response of right
ventricular systolic pressure above 45 millimetres of
mercury during exercise in healthy, normal indivi-
duals,12 and also in healthy carriers of mutations in
the bone morphogenetic protein receptor type 2
gene.13 Such abnormal responses have been shown
to be a marker of susceptibility to high altitude
pulmonary oedema.14 Some investigators have also
shown abnormal responses in endurance-trained
professional athletes,15 whereas others demonstrated
a normal response.3 It has been hypothesized that
the extremely high cardiac output of such athletes
exceeds their pulmonary vascular dilative capacity,
and thereby may lead to pulmonary vascular
pressures above normal limits.1,15
The pulmonary endothelium is adapted to
conditions of low blood pressure. Endothelial
damage is well known in different kinds of
pulmonary arterial hypertension. In patients with
Eisenmenger syndrome, who have untreated or
complicated congenital cardiac malformations,
shunting of blood from the systemic to the
pulmonary circulations results in excessive pulmon-
ary flow and endothelial sheer stress.16
We are not aware of any major studies on the
normal range of either right ventricular or pulmonary
arterial systolic pressures during exercise in healthy
adolescents, including non-professional high perform-
ing athletes. Exercise echocardiography is of increas-
ing importance as a diagnostic tool in pulmonary
hypertension, and normal values of right ventricular
systolic pressure during exercise are strongly needed.
In this study, therefore, we aimed to investigate the
normal range, in particular the upper normal limit,
of right ventricular systolic pressure in adolescents
and young adults during exercise, as measured by
non-invasive ultrasonic techniques. Additionally, we
aimed to investigate the interrelation of right
ventricular systolic pressure to the aerobic exercise
capacity, and to establish whether endurance-trained
athletes differ from the normally trained population.
Materials and methods
Population
Healthy volunteers were recruited from hospital
employees and their relatives, among college
students of a nearby institution, and among local
inhabitants. The volunteers were aged between 13
and 25 years, because an age- and gender-matched
control group was needed at ratios of 2 to 1 for
research in a young population of 45 subjects with
congenital cardiac disease. The volunteers had no
known heart or lung disease, albeit that mild
bronchial asthma was accepted. Detection of any
cardiac condition, or any serious lung condition,
during the study led to exclusion.
Examination
The clinical investigation consisted of cardiopul-
monary exercise testing on a treadmill, along with
electrocardiography and echocardiography at rest
and during exercise on a supine cycle ergometer.
The participants performed a maximal exercise test
with gas exchange analysis and electrocardiogram
on a treadmill ergometer following the Oslo
protocol17 (Equipment: Jaeger Oxycon Delta,
VIASYS Healthcare, Ho¨chberg, Germany). Peak
oxygen uptake was corrected for body weight18 and
expressed as ml kg20.67min21.
The individual results were compared to reference
values from healthy Norwegian adolescents,19 and
expressed by standard deviation, the Z-score, from
the age-related mean in the reference material.
Highly endurance trained individuals with a Z-
score above 2.0 were defined as athletes. The others,
with Z-scores equal or less than 2.0, were defined as
normally trained subjects.
All echocardiographic recordings were obtained
with a Vivid 7 Dimension scanner (GE Vingmed
Ultrasound, Horten, Norway) and the studies were
both videotaped and stored digitally. Echocardio-
graphy at rest included standard views and
measurements. Right atrial pressure at rest was
estimated by inferior caval venous index,20 and the
following additional specific measurements of right
ventricular performance21–24 were also included:
> Tricuspid annular plane systolic excursion in
millimetres measured in M-mode.25
> Tricuspid annulus peak systolic velocity in
centimetres per second by colour tissue Doppler
imaging and by pulsed tissue Doppler ima-
ging.26,27
Approximately 1 hour after treadmill testing,
exercise echocardiography was performed during
supine cycling with about 30 degrees head elevation
and 30 degrees left side tilt (Equipment: Ergoselect
1200 EL, Ergoline, Bitz, Germany). The stepwise
World Health Organisation exercise protocol was
used with a starting load of 25 Watt and an increase
by 25 Watt every second minute until the target
heart rate of 1602min was reached. Above that level,
echocardiographic recordings become futile because
of upper body movement and interposition of the
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lungs. Systemic blood pressure was measured at
every exercise level, as well as the maximal velocity
of tricuspid regurgitation jet. The right ventricular
systolic pressure was calculated from each recording
by means of the modified Bernoulli equation,
adding the right atrial pressure at rest to the
calculated pressure gradient between right ventricle
and right atrium (right ventricular systolic pressure
5 4V21[right atrial pressure]).6
In order to detect dynamic right ventricular
outflow tract obstruction that could interfere with
right ventricular systolic pressure measurements, an
attempt was made to measure right ventricular
outflow tract velocity at the 100 Watt level.
Outflow tract velocities higher than 2 meters per
second lead to exclusion from the study.
Data analysis
Pressure measurements were made offline by analysis
of all digitally stored still images of tricuspid
regurgitation velocity. Every frame was classified as
a good, reasonable or poor/impossible measurement.
For every minute of exercise, measurements were
summarized into a conclusive pressure value (max-
imum of two values per workload level) based on the
best accessible Doppler measurements. Obvious
outlier measurements were ignored. For approval of
the entire exercise study at least the second last
passed workload level had to be evaluable.
For analysis of inter-observer variability, a
blinded second analyser evaluated 35 exercise
echocardiographic recordings from study partici-
pants and from patients with atrial or ventricular
septal defects in a similar exercise study setting. The
second analyser was experienced in exercise echo-
cardiography technique. Inter-observer agreement
was expressed by a Bland-Altman-plot28 and by
Kappa statistics.29 Variability was also expressed as
deviation (%) from the average of both analysers.
Data storage and statistical analysis were exe-
cuted with Microsoft Access 2003, Microsoft Excel
2003, SPSS 12.1/16.0, Analyse-it 2.11 and Sigma-
Plot 11.0. Offline analyses of ultrasound studies
were performed on EchoPac PC 5.x (GE Vingmed
Ultrasound, Horten, Norway).
Statistics
Student t-tests were performed to compare different
subgroups if normal distribution was assumed.
Otherwise, nonparametric tests were used for con-
tinuous variables and Chi square for categorical
variables. Pearson’s correlation was used to determine
relation between different independent variables. A
multivariate linear regression model, using the
stepwise backwards elimination procedure, was used
to model the relation between independent variables,
specifically age, gender, exercise habits, Z-score of
peak oxygen uptake, tricuspid annular plane systolic
excursion and tricuspid annular peak systolic
velocity, and outcome variable maximal right
ventricular systolic pressure during exercise. p-values
lower than 0.05 were considered statistically sig-
nificant. Inter-observer variability for continuous
variables was calculated by intraclass correlation
coefficient. For categorical variables, inter-observer
agreement was calculated by kappa statistics.
Approvals
The study complies with the Declaration of
Helsinki, and it was approved by the Regional
Committee for Medical Research Ethics, with all
participants giving their informed consent, minors
by proxy. The authors had full access to the data and
take responsibility for its integrity. All authors have
read and agree to the manuscript as written.
Results
We recruited 113 healthy volunteers, who passed all
examinations (Table 1).
Aerobic capacity characteristics
The aerobic capacity was normally distributed (Fig. 1),
with a mean Z-score of 0.31 related to the reference
study.19 Of the individuals, 13 (11.5%), with 6
female, were athletes having Z-scores higher than
2.0, and 8 of these were aged from 16 to 18 years.
The athletes performed different kinds of sports,
including cross country skiing, soccer, badminton,
volleyball, handball, and running, and they fol-
lowed a training programme on a non-professional
level beside their daily school or working activity.
Cardiac characteristics
We found 3 cases of right bundle branch block in
the electrocardiogram at rest, 2 in normally trained
subjects and 1 in an athlete, but no incidents of
arrhythmia or bundle branch block occurring
during exercise. All values for shortening fraction,
right ventricular systolic pressure at rest, tricuspid
annular plane systolic excursion, tricuspid annular
peak systolic velocity and pulsed tricuspid annular
peak systolic velocity were within normal limits and
normally distributed (Table 2).
Exercise echocardiography/right ventricular systolic
pressure characteristics
We obtained assessable echocardiography recordings
in 109 individuals (96%), among whom 12 were
athletes. Maximal right ventricular systolic pressure
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during exercise showed a skewed distribution
towards high levels, while right ventricular systolic
pressure in the normally trained group alone was
normally distributed. For the whole group of 109
subjects, the maximal right ventricular systolic
pressure during exercise showed a median of 39.0
millimetres of mercury, with a range from 17 to 69,
and the 90th and 95th percentiles were 51 and
60 millimetres of mercury, respectively. In
the normally trained group, the maximal right
ventricular systolic pressure showed a mean of 38.0
millimetres of mercury, with standard deviation of
7.2, a median of 39.0, and a range from 17 to 63,
with 90th and 95th percentiles at 46 and 51
millimetres of mercury. The athletes had a median
maximal right ventricular systolic pressure of 55.5
millimetres of mercury, with a range from 28 to 69.
The difference in maximal right ventricular systolic
pressure during exercise between the normally
trained group and the athletes was statistically
Table 1. Demographics and basic characteristics.
Age group (years) N male/female Age Mean Height (cm) Mean6 SD Weight (kg) Mean6 SD BMI (kg/m2) Mean6 SD
13–15 22 15/13 14.1 170.66 11.9 62.06 12.3 21.16 2.6
16–18 19 22/19 16.9 168.96 8.8 62.66 11.6 21.86 3.2
19–21 18 4/18 20.2 175.06 8.6 68.36 10.7 22.26 2.1
22–25 21 8/14 23.3 171.86 9.7 65.66 17.1 22.06 4.4
Overall/sum 113 49/64 18.1 171.16 9.9 64.16 12.9 21.86 3.1
SD5 standard deviation, BMI5 body mass index.
Figure 1.
Normal distribution of Z-score in peak oxygen uptake (n5113).
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significant, the Mann-Whitney test giving a value
of p equal to 0.004 (Fig. 2).
In order to investigate whether low aerobic
capacity could be caused by abnormal right
ventricular systolic pressure, we compared the
subgroup of 8 with lowest peak oxygen uptake,
and Z-scores below 22.0, with the normal group
having Z-scores between 22.0 and 2.0, but found
no difference in maximal right ventricular systolic
pressure. For the entire normally trained group,
there was no correlation between peak oxygen
uptake and maximal right ventricular systolic
pressure.
Normal and abnormal responders in terms of
right ventricular systolic pressure, taking a cut-off
for maximal right ventricular systolic pressure of
greater than 50 millimetres of mercury, showed a
similar pattern of slow and parallel rise of right
ventricular systolic pressure and systemic systolic
blood pressure during incremental exercise (Figs 3
and 4). Normal responders reached a plateau at a
moderate level for exercise, whereas abnormal
responders showed a continuous increase of systolic
pressure throughout the entire duration of exercise
(Fig. 3).
Of the 12 athletes, 10 (83%) had maximal right
ventricular systolic pressures higher than 40 milli-
metres of mercury, as compared to 44 of the 97 (45%)
Figure 2.
Maximal right ventricular systolic pressure (RVSP) during
exercise in normally trained individuals and athletes. For normal
trained group there are two outliers between 1.5 and 3 box lengths
outside boxes edge, one extreme case outside . 3 box lengths.
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normally trained subjects (p5 0.025). When using
45 millimetres of mercury as the cut off, the
respective number of abnormal responders were 8 of
12 (67%) for athletes, and 16 of 97 (16%) for
normally trained subjects (p, 0.001). With 50
millimetres of mercury taken as the cut-off, the
respective numbers were again 8 of 12 (67%) for the
athletes, but only 8 of 97 (8%) of the normally
trained subjects (p, 0.001) (Table 3).
Linear regression analysis showed that age,
gender, body mass index, exercise habits, Z-score
of peak oxygen uptake, tricuspid annular plane
systolic excursion and tricuspid annular peak
systolic velocity did not have a significant pre-
dictive value for maximal right ventricular systolic
pressure during exercise.
There was no difference in maximal right
ventricular systolic pressure between 9 smokers
and 98 non-smokers. For females there was no
difference in maximal right ventricular systolic
pressure between groups with regard to use of oral
contraceptives.
Inter-observer variability
The analyses made by the 2 independent observers
showed very good agreement. The 95% limits of
agreement were20.17/0.33 metres per second, with
a positive bias of 0.06 metres per second in Doppler
velocity measurements and 2 millimetres of mercury
in maximal right ventricular systolic pressure
between the first and second analyser (Fig. 5). There
was no difference in agreement depending on low or
high velocities. For tricuspid regurgitation velocities
measured offline by the two observers, the intraclass
correlation coefficient was 0.934 (p, 0.001).
In order to define abnormal pressure response to
exercise, it was possible to measure inter-observer
agreement for a nominal variable by Kappa
statistics. With a cut-off of 45 millimetres of
mercury, Kappa was 0.79, while with a cut-off of 50
millimetres of mercury, Kappa was 0.82. Following
commonly used definitions, kappa from 0.6 to 0.8
means good agreement, while kappa above 0.8
means very good agreement.
Discussion
Our data has shown a great variability in right
ventricular pressure response to exercise. There is no
linear correlation between maximal right ventricu-
lar systolic pressure and aerobic capacity, but
athletes with high aerobic capacity often show an
abnormally high response. The upper normal limit
of the response in normally trained individuals
seems to be higher than commonly assumed.9
The number of examined individuals in our study
is high compared to other studies with a comparable
focus that investigated mixed groups of normally
trained subjects and athletes made up of 203 to 40
individuals.1 Our study group has a sufficient
distribution of age and gender to allow conclusions
to be drawn concerning adolescents and young
adults. This is also supported by results for peak
uptake of oxygen, which reflect reference values.
The strong correlation between non-invasive
and invasive measurements has previously been
Figure 3.
Right ventricular systolic pressure (RVSP) during exercise in
subjects with abnormal right ventricular systolic pressure response
(AR) and normal response (non-AR) with cut-off right
ventricular systolic pressure 50 mmHg. After 15 minutes, there
were too few measurements to permit calculation of confidence
intervals.
Figure 4.
Systolic blood pressure during exercise in subjects with abnormal
right ventricular systolic pressure response (AR) and normal
response (non-AR) with cut-off right ventricular systolic pressure
50 mmHg. After 175 Watt workload, there were too few
measurements for calculation of confidence intervals.
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demonstrated both at rest and during exercise.6,7,20
Thus conclusions about the response of pulmonary
arterial pressure can rely, therefore, on entirely non-
invasive protocols, albeit that normal values for
exercise echocardiography have not previously been
established. Our findings, nonetheless, confirm
earlier statements7 that exercise echocardiography
as a reliable tool for assessment of the response of
right ventricular pressure during exercise.
The high rate of quantifiable tests as compared to
previous studies,30 and a high degree of inter-
observer agreement, reflects the technical progress.
Modern ultrasound scanners and digital storage of
image information facilitate detection and precise
determination of small tricuspid regurgitation
signals.
Doppler signal profiles of tricuspid regurgitation
velocities during exercise are of variable quality, and
not always easy to interpret. Signal drop-out often
occurs in the middle of the profile. Measurement of
the angle of velocity may be disturbed during
exercise because of increased translation movement
of the heart and narrowing of the area of good
ultrasonic access with increasing excursion of the
thorax. The described non-invasive method includes
the assumption that right atrial pressure remains
unchanged during exercise. From invasive studies,7
we know that this assumption may not be totally
correct, leading to a slight underestimation of
pulmonary arterial pressure during exercise.
All of these technical issues potentially cause a
certain underestimation of the response of right
ventricular systolic pressure, and none would cause
overestimation. The low inter-observer-variation
confirms the high accuracy in pressure measure-
ments.
Thus, in the absence of any obstruction to right
ventricular outflow, our current non-invasive data
allows conclusions to be drawn about pulmonary
arterial pressure and pulmonary vascular resistance,
though these parameters had not been measured.
And pulmonary hemodynamics during exercise are
in focus when seeking early signs of pulmonary
vasculopathy.
In our study, we performed exercise echocardio-
graphy 1 hour after a maximal treadmill exercise
test. This may have lowered pulmonary and
systemic resistance, resulting in false low levels of
pulmonary pressure. For that reason, as well as
technical ones, our protocol may have caused
underestimation of the response of pulmonary
pressure. There are several possible ways, therefore,
Table 3. Abnormal right ventricular systolic pressure response during exercise in normally trained group and athletes.
Cut-off 40mmHg Cut-off 45mmHg Cut-off 50mmHg
Study group N N (%) N (%) N (%)
Normally trained group 97 44 (45%) 16 (16%) 8 (8%)
Athletes 12 10 (83%) 8 (67%) 8 (67%)
Chi square significance (p) 0.025 ,0.001 ,0.001
Figure 5.
Bland-Altman-Plot of inter-observer variability in measurements of the velocity of the jet of tricuspid regurgitation.
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of underestimating pulmonary arterial systolic
pressure by non-invasive measurement of right
ventricular systolic pressure, but no obvious risk
of overestimating it.
The normal range of right ventricular systolic
pressure during exercise in our material is wider
than in previous studies. The Gaussian distribution
of maximal right ventricular systolic pressure in
normally trained subjects confirms a high variability
of pressure response as a physiological phenomenon
rather than a technical or methodical artefact.
The data we have presented confirms a strong
interrelation between high aerobic capacity and an
abnormal response of right ventricular systolic
pressure. The fact that separation of athletes from
the normal trained group lead to normal distribu-
tion in maximal right ventricular systolic pressure
during exercise suggests a specific physiological
mechanism in athletes leading to high right
ventricular and pulmonary pressure during exercise.
This is also supported by the significant difference
in the abnormal response between normal trained
individuals and athletes. Cardiac output, alveolar
gas diffusion and pulmonary vascular resistance
were not monitored during exercise. Thus, our data
does not allow a conclusion to be drawn about the
theory that elevated pulmonary arterial pressure in
athletes is caused by high cardiac output and
limited dilative capacity on the pulmonary ves-
sels.1,15 The data did not give any evidence that
high right ventricular systolic pressure during
exercise reduces aerobic capacity in healthy indivi-
duals, since there was no difference in right
ventricular systolic pressure between normally
trained and totally untrained individuals.
Like earlier studies1,15 we found that normally
responding individuals reach a plateau in right
ventricular systolic pressure, whereas individuals
with an abnormal response continue to increase both
their right ventricular and pulmonary arterial
systolic pressures. There was no sudden increase of
pulmonary or systemic vascular resistance in
individuals with an abnormal response. The
continuous increase of right ventricular systolic
pressure in individuals showing an abnormal
response cannot be explained by recent theories of
sympathoexcitation and its influence on vasocon-
striction in the pulmonary arterioles.31 Because of
their different physiology, we had to exclude the
athletes in order to define normality in right
ventricular systolic pressure. This leads to an upper
limit of 50 millimetres of mercury for the normal
response to exercise in healthy normally trained
young individuals. Given that right ventricular
systolic pressure reflects pulmonary arterial systolic
pressure, 50 millimetres of mercury pulmonary
arterial systolic pressure calculated into mean
pulmonary arterial pressure results in 32.5 milli-
metres of mercury when using the formula
(PAMP5 0.61 *PASP1 2mmHg)m4 where PAMP
and PASP are the mean and systolic pulmonary
arterial pressure respectively. The result of 32.5
fits with the definition of exercise-induced pul-
monary hypertension as mean pulmonary arterial
pressure higher than 30 millimetres of mercury
during exercise.5
Our results challenge the commonly used value of
40 or 45 millimetres of mercury as the upper limit
of the normal response of right ventricular systolic
pressure to exercise. The acceptance of a higher
upper limit for normal pressure may lead to a more
restrictive definition and reduced prevalence of
exercise-induced pulmonary arterial hypertension.
In conclusion, we have shown exercise echocar-
diography to be a reliable tool in measuring right
ventricular systolic pressure during exercise. Our
study demonstrates a high variability in the
response of this pressure to exercise among
adolescents and young adults. According to our
findings, 50 millimetres of mercury is the upper
limit of the normal response to exercise in healthy
normally trained subjects. The common definition
of the normal range in right ventricular and
pulmonary arterial pressures during exercise may
have to be reconsidered.
Young non-professional endurance-trained ath-
letes show an abnormally high response during
exercise, with two-thirds exceeding 50 millimetres
of mercury. This has to be taken in account in the
selection of controls in clinical studies of exercise-
induced pulmonary hypertension
Acknowledgments
We thank Ekkehard Gru¨nig and Derliz Mereles, of
the University Hospital of Heidelberg, Germany,
for generously sharing their experience in exercise
echocardiography during the planning of the
presented study. We also thank Eileen Wittmann,
of the Pediatric Department, Vestfold Hospital Trust
for her critical review of grammar and style of the
manuscript. Are Hugo Pripp, of the Biostatistics
Unit, Rikshospitalet, kindly advised with regard to
statistical analysis.
Funding: This work was supported by:
– EXTRA funds from the Norwegian Foundation
for Health and Rehabilitation
– Research funding by the Southern and South-
Eastern Norway Regional Health Authority
– Private research funds located at Vestfold
Hospital Trust.
472 Cardiology in the Young October 2009
Equipment was partly financed by the National
Parents Association ‘‘Foreningen For Hjertesyke
Barn’’(FFHB) and the Hospital’s Friends Foundation
in the county of Vestfold (‘‘Sykehusets Venner’’).
References
1. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF.
Range of tricuspid regurgitation velocity at rest and during
exercise in normal adult men: implications for the diagnosis of
pulmonary hypertension. J Am Coll Cardiol 1999; 33:
1662–1666.
2. Gurtner HP, Walser P, Fa¨ssler B. Normal values for pulmonary
hemodynamics at rest and during exercise in man. Prog Resp Res
1975; 9: 295–315.
3. Janosi A, Apor P, Hankoczy J, Kadar A. Pulmonary artery
pressure and oxygen consumption measurement during supine
bicycle exercise. Chest 1988; 93: 419–421.
4. Chemla D, Castelain V, Provencher S, Humbert M, Simonneau G,
Herve P. Evaluation of various empirical formulas for estimating
mean pulmonary artery pressure by using systolic pulmonary
artery pressure in adults. Chest 2009; 135: 760–768.
5. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential
assessment of pulmonary arterial hypertension. J Am Coll Cardiol
2004; 43: 40S–47S.
6. Yock PG, Popp RL. Noninvasive estimation of right ventricular
systolic pressure by Doppler ultrasound in patients with tricuspid
regurgitation. Circulation 1984; 70: 657–662.
7. Himelman RB, Stulbarg M, Kircher B, et al. Noninvasive
evaluation of pulmonary artery pressure during exercise by saline-
enhanced Doppler echocardiography in chronic pulmonary
disease. Circulation 1989; 79: 863–871.
8. Kaplan JD, Foster E, Redberg RF, Schiller NB. Exercise Doppler
echocardiography identifies abnormal hemodynamics in adults
with congenital heart disease. Am Heart J 1994; 127:
1572–1580.
9. Vachie´ry J, Pavelescu A. Exercise echocardiography in pulmonary
hypertension. Eur Heart J Suppl 2007; 9: H48–H53.
10. Callejas-Rubio JL, Moreno-Escobar E, Martin-de la FP, Ortego-
Centeno N. Pulmonary hypertension and exercise echocardio-
graphy. Eur J Echocardiogr 2006; 7: 261–262.
11. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary
hypertension. A national prospective study. Ann Intern Med
1987; 107: 216–223.
12. Chenivesse C, Rachenne V, Fournier C, et al. Cardiopulmonary
exercise testing in exercise-induced pulmonary hypertension. Rev
Mal Respir 2006; 23: 111–113.
13. Grunig E, Janssen B, Mereles D, et al. Abnormal pulmonary artery
pressure response in asymptomatic carriers of primary pulmonary
hypertension gene. Circulation 2000; 102: 1145–1150.
14. Grunig E, Mereles D, Hildebrandt W, et al. Stress Doppler
echocardiography for identification of susceptibility to high altitude
pulmonary edema. J Am Coll Cardiol 2000; 35: 980–987.
15. Bossone E, Vriz O, Bodini BD, Rubenfire M. Cardiovascular
response to exercise in elite ice hockey players. Can J Cardiol
2004; 20: 893–897.
16. Granton JT, Rabinovitch M. Pulmonary arterial hypertension in
congenital heart disease. Cardiol Clin 2002; 20: 441–457.
17. Fredriksen PM, Ingjer F, Nystad W, Thaulow E. Aerobic
endurance testing of children and adolescents – a comparison of
two treadmill-protocols. Scand J Med Sci Sports 1998; 8:
203–207.
18. Pettersen SA, Fredriksen PM, Ingjer E. The correlation between
peak oxygen uptake (VO2peak) and running performance in
children and adolescents. aspects of different units. Scand J Med
Sci Sports 2001; 11: 223–228.
19. Fredriksen PM, Ingjer F, Nystad W, Thaulow E. A comparison of
VO2(peak) between patients with congenital heart disease and
healthy subjects, all aged 8–17 years. Eur J Appl Physiol Occup
Physiol 1999; 80: 409–416.
20. Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation
of right atrial pressure from the inspiratory collapse of the inferior
vena cava. Am J Cardiol 1990; 66: 493–496.
21. Friedberg MK, Rosenthal DN. New developments in echocardio-
graphic methods to assess right ventricular function in congenital
heart disease. Curr Opin Cardiol 2005; 20: 84–88.
22. Lee CY, Chang SM, Hsiao SH, Tseng JC, Lin SK, Liu CP. Right
heart function and scleroderma: insights from tricuspid annular
plane systolic excursion. Echocardiography 2007; 24: 118–125.
23. Saxena N, Rajagopalan N, Edelman K, Lopez-Candales A. Tricuspid
annular systolic velocity: a useful measurement in determining right
ventricular systolic function regardless of pulmonary artery
pressures. Echocardiography 2006; 23: 750–755.
24. Tamborini G, Pepi M, Galli CA, et al. Feasibility and accuracy of
a routine echocardiographic assessment of right ventricular
function. Int J Cardiol 2007; 115: 86–89.
25. Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right
ventricular function using two-dimensional echocardiography.
Am Heart J 1984; 107: 526–531.
26. Meluzin J, Spinarova L, Bakala J, et al. Pulsed Doppler tissue
imaging of the velocity of tricuspid annular systolic motion; a
new, rapid, and non-invasive method of evaluating right
ventricular systolic function. Eur Heart J 2001; 22: 340–348.
27. Alam M, Wardell J, Andersson E, Samad BA, Nordlander R.
Characteristics of mitral and tricuspid annular velocities
determined by pulsed wave Doppler tissue imaging in healthy
subjects. J Am Soc Echocardiogr 1999; 12: 618–628.
28. Bland JM, Altman DG. Measuring agreement in method
comparison studies. Stat Methods Med Res 1999; 8: 135–160.
29. Altman DG. Practical statistics for medical research. Chapman
and Hall, London, 1991.
30. Borgeson DD, Seward JB, Miller FA Jr, Oh JK, Tajik AJ.
Frequency of Doppler measurable pulmonary artery pressures.
J Am Soc Echocardiogr 1996; 9: 832–837.
31. Lykidis CK, White MJ, Balanos GM. The pulmonary vascular
response to the sustained activation of the muscle metaboreflex in
man. Exp Physiol 2008; 93: 247–253.
Vol. 19, No. 5 Mo¨ller et al: Non-invasive measurement of right ventricular pressure 473

II

III

IV

MÖLLER 
A novel BMPR-2 gene mutation associated with exercise-induced 
pulmonary hypertension in septal defects 
Short title:  BMPR-2 gene mutations in septal defects 
 
 
Thomas Möller1 MD, Trond P Leren2 PhD, Kristin L Eiklid2 PhD, Henrik Holmstrøm3
PhD, Per Morten Fredriksen4 PhD, Erik Thaulow3 PhD
1 Pediatric Department, Vestfold Hospital Trust, Tønsberg, Norway  
2 Department of Medical Genetics, Oslo University Hospital, Oslo Norway 
3 Department of Pediatric Cardiology, Pulmology and Allergy, Oslo University 
Hospital Rikshospitalet, Oslo, Norway 
4 Clinical Trials Unit, Oslo University Hospital, Oslo, Norway 
 
 
Address reprint requests to:
Thomas Möller, MD 
Pediatric Department, Vestfold Hospital Trust 
Postboks 2168 Postterminalen, N-3103 Tønsberg, Norway 
E-mail: thomas.moller@siv.no, Phone: +47 33342000, Fax: +47 33343975 
 
Presentation / meetings: 
If the manuscript is unpublished by June 2, 2010, the abstract will be submitted to Scientific 
Sessions 2010 of the American Heart Association.
1 
MÖLLER 
Abstract: 
Objective: Our study aimed to investigate the relationship between exercise-induced 
pulmonary arterial hypertension and genetic changes related to the transforming growth 
factor- (TGF-) signaling pathway in patients with cardiac septal defects. 
Design: In a population-based group of 44 patients (age 13 – 25 years) with either isolated 
ventricular septal defect (n=27) or isolated atrial septal defect (n=17), right ventricular 
systolic pressure response to submaximal exercise was studied by echocardiography and 
classified as normal ( 45 mmHg), borderline (45-50 mmHg) or abnormal (>50 mmHg). 
Genes related to TGF- were analyzed by DNA sequencing and multiplex ligand-dependent 
probe amplification. None of the patients were related. 
Results: Pressure response was borderline in 5 and abnormal in 9 patients. Five patients 
showed mutations in exon 12 of the bone morphogenetic protein receptor type 2 gene: 3 
patients with normal pressure response were heterozygous for the benign mutation S775N (c. 
2324, G>A), 2 patients with borderline/abnormal pressure response were heterozygous for the 
probably pathogenic mutation Y589C (c.1766, A>G) which has not been previously 
described. 
Conclusion: Genetic changes in TGF- related genes may be overrepresented in patients with 
cardiac septal defects and exercise-induced pulmonary hypertension.
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Abbreviations: 
ALK1   activin receptor-like kinase 1 
ASD   atrial septal defect 
BMPR2  bone morphogenetic protein receptor type 2 
FPAH   familial pulmonary arterial hypertension 
MLPA   multiplex ligation-dependent probe amplification 
PAH   pulmonary arterial hypertension 
RVSP   right ventricular systolic pressure 
TGF-beta  transforming growth factor- 
VSD   ventricular septal defect 
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Introduction: 
 
Proteins of the transforming growth factor- (TGF-) signaling pathway have been shown to 
be important prenatally in cardiac and pulmonary vascular development (1-4) as well as in the 
postnatal pathogenesis of pulmonary arterial hypertension (PAH).(5-8) Bone morphogenetic 
protein type 2 (BMP2) is crucial in coordinating multiple aspects of atrioventricular canal 
morphogenesis (4) and cardiac looping.(1) Mutations in the bone morphogenetic protein 
receptor type 2 (BMPR-2) coding gene have been identified in familial PAH (FPAH) (6) and 
in about 25% of sporadic cases of idiopathic PAH.(9) In a mixed group of patients with 
congenital heart disease and secondary PAH, BMPR-2 gene mutations have been 
demonstrated in 6% of cases.(10) In patients with atrial septal defect (ASD) with or without 
Eisenmenger syndrome no mutations were found.(11) In patients with Hereditary 
Hemorrhagic Teleangiectasia (Osler-Weber-Rendu syndrome) and associated PAH, mutations 
of two other TGF- genes have been identified: activin receptor-like kinase 1 (ALK1) (12) 
and endoglin (ENG).(13) 
 
Occurrence of secondary PAH with small open septal defects and even many years after 
surgical defect closure, has been reported in patients without indications of perioperative 
PAH.(14;15) Echocardiography has been shown to give reliable measurements of right 
ventricular systolic pressure (RVSP) compared to invasive measurement at rest (16) and 
during exercise.(17)  In the absence of right ventricular outflow tract obstruction, RVSP 
reflects pulmonary arterial systolic pressure.(18-20)  
 
The role of genetics in patients with congenital heart disease and secondary PAH has yet to be 
defined. We have found exercise-induced PAH in 25% of adolescents with cardiac septal 
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defects.(21) We aimed to investigate the relationship between exercise-induced PAH in this 
group of patients and genetic changes related to the TGF- signaling pathway. The hypothesis 
is that genetic changes would predispose to exercise-induced PAH. 
Material and methods: 
 
According to medical registries in the Norwegian regions of Vestfold, Asker and Bærum, 69 
children were born between 1982 and 1993 with isolated ventricular septal defect (VSD) or 
isolated ASD. Exclusion criteria were right ventricular outflow tract obstruction, spontaneous 
defect closure during follow-up and complicating conditions preventing appropriate exercise 
testing (i.e. trisomy 21). Two individuals with device-closed ASD were excluded to prevent 
device related confounding. The 67 eligible patients had at the time of inclusion either an 
open defect or they had undergone surgical defect closure. Twenty-three patients were lost to 
follow-up or refused participation. Consequently, a population-based group of 44 individuals 
(age 13 – 25 years) with isolated ASD (n=17) or isolated VSD (n=27) could be included.  
There were no family relationships between any of the patients. A control group for genetical 
results was not included; a comparison between the patient group and a matched control 
group in terms of baseline and exercise hemodynamic results has been described 
previously.(21) 
Hemodynamic assessment 
 
Echocardiographic recordings were obtained with a Vivid 7 scanner (GE Vingmed 
Ultrasound, Horten, Norway). All echocardiographic studies were videotaped and saved 
digitally (still frame and loops). Right atrial pressure at rest was estimated by vena cava 
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inferior index.(22) Exercise echocardiography was performed during supine cycling with 
about 30 degrees elevation and left side tilt (Equipment: Ergoselect 1200 EL, Ergoline GmbH, 
Bitz, Germany). A stepwise exercise protocol was used with a starting load of 25 Watt and an 
increase of 25 Watt every second minute until the target heart rate of 160-min was reached. 
Above that level, echocardiographic recordings become futile because of upper body 
movement and interposition of the lungs. The maximal velocity of tricuspid regurgitation jet 
was measured at every exercise level. The RVSP was calculated from each recording by 
means of the modified Bernoulli’s equation, adding the right atrial pressure at rest to the 
calculated pressure gradient between right ventricle and right atrium.(16) In order to detect 
dynamic right ventricular outflow tract obstruction that could interfere with RVSP 
measurements, right ventricular outflow tract velocity was measured at the 100 Watt level. 
Patients with outflow tract velocities higher than two meters per second were not included in 
the study. Maximal RVSP from 46 mmHg through 50 mmHg during exercise was defined as 
borderline, maximal RVSP exceeding 50 mmHg was defined as abnormal.(23) 
Pressure measurements were made offline by analysis of all digitally stored still frames of 
tricuspid regurgitation velocity. Offline analysis of ultrasound studies were performed on 
EchoPac PC 5.x (GE Vingmed Ultrasound, Horten, Norway). Every frame was classified into 
good, reasonable or not analyzable measurement. For every minute of exercise, measurements 
were summarized into a conclusive pressure value (maximum of two values per workload 
level) based on the best accessible Doppler measurements. Obvious outlier measurements 
with major deviation from both previous and subsequent measurements were rejected. For 
approval of the entire exercise study at least the second last passed workload level had to be 
evaluable. 
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Genetical analysis  
 
Screening for mutations in the BMPR-2 gene (GenBank accession number Z48923.1) was 
performed by DNA sequencing to detect point mutations and small insertions/deletions within 
exons and the flanking intron sequences, and by multiplex ligation-dependent probe 
amplification (MLPA) to detect structural alterations. For DNA sequencing, DNA was 
extracted from EDTA-containing blood by the use of a BioRobot EZ1 (Qiagen GmbH, 
Hilden, Germany). Individual exons with flanking intron sequences were amplified by PCR. 
Typically, approximately 50 base pairs of flanking intron sequences were included in the 
amplicons. The primer sequences and conditions for the thermal cyclings are available upon 
request. Standard DNA sequencing reactions using version 3.1 of Big Dye terminator cycle 
sequencing kit (Applied Biosystems Inc., Foster City, CA) were analyzed on a Genetic 
Analyzer 3730 (Applied Biosystems Inc., Foster City, CA). The software prediction program 
PolyPhen (www.bork.embl-heidelberg.de/PolyPhen/) was used to assess the pathogenicity of 
identified missense mutations. For MLPA analysis, DNA was extracted from EDTA-
containing white blood lymphocytes by the manufacturer’s protocol, on a Magnapure DNA 
Extractor (Roche Diagnostics GmbH, Mannheim, Germany). The SALSA MLPA kit P093 
HHT/PPHT1 (MCR-Holland, Amsterdam, The Netherlands) was used to test for deletions or 
duplication in the BMRP-2 gene, the ENG gene and the ALK1 gene. 
The study complies with the Declaration of Helsinki. It was approved by the Regional 
Committee for Medical Research Ethics and all participating subjects gave informed consent. 
The authors had full access to the data and take responsibility for its integrity. All authors 
have read and agreed to the manuscript as written. 
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Results:
The study included 44 patients (17 ASD, 27 VSD) (table 1). All patients with ASD had a 
surgically closed defect. Sixteen VSD patients were not operated and had a small open septal 
defect (either muscular or perimembraneous). Velocity measurements across the ventricular 
septum in these patients revealed high pressure gradients (4.5±0.51 m/s) indicating normal 
systolic pressure conditions in both heart chambers at rest. Eleven patients had their VSD 
closed surgically. No patient had a history of preoperative PAH. Two of the operated patients 
with VSD (18%) had minor residual shunts with normal pressure conditions at rest. Median 
age at the time of defect closure was 53 months for ASD patients and 61 months for VSD 
patients. None of the patients had family members with congenital heart disease or known 
PAH within two generations. 
 
There was no case of pulmonary hypertension at rest (RVSP > 40 mmHg). Exercise 
echocardiography permitted assessable measurements of RVSP by tricuspid regurgitation jet 
velocity in all patients. Five patients showed borderline RVSP and 9 patients had abnormal 
RVSP during exercise (table 2). 
Two subjects were found to be heterozygous for mutation Y589C (c.1766, A>G) in exon 12 
of the BMPR-2 gene and three were found to be heterozygous for mutation S775N (c. 2324, 
G>A) in exon 12 (table 2). Analysis of the pathogenicity of two mutations by the use of the 
prediction program PolyPhen, revealed that mutation Y589C was predicted to be “Probably 
damaging”. S775N was predicted to be “Benign” and has been found in healthy controls 
subjects by other investigators.(24) None of the subjects had deletions or duplication in the 
BMPR-2 gene, the ENG gene or the ALK1 gene. 
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Discussion: 
 
Our study demonstrates the presence of genetic changes related the TGF- signaling pathway 
in patients with cardiac septal defect and borderline or abnormal RVSP response to 
submaximal exercise. To our knowledge mutation Y589C in the BMPR-2 gene is a novel 
mutation predicted by PolyPhen to be pathogenic, whereas mutation S775N has been 
previously reported (24) and has also been found in healthy controls.(25) 
 
Exercise-induced PAH characterized by abnormal RVSP increase during exercise is 
considered being a marker of early pulmonary vasculopathy in FPAH.(26;27) Detection of 
exercise-induced PAH identifies carriers of BMPR-2 gene mutations in FPAH.(26;28) An 
animal study has demonstrated that targeted genetic ablation of the BMPR-2 gene in the 
pulmonary vascular endothelium predisposes to PAH. Congenital heart malformations with 
left-to-right shunt like ASD and VSD lead to volume overload or combined pressure and 
volume overload in the pulmonary vascular system. Pressure and volume cause endothelial 
stretch that in turn leads to pulmonary vasculopathy and eventually results in PAH.(29) Our 
data support the hypothesis of genetical susceptibility to PAH when the pulmonary vascular 
endothelium is exposed to abnormal hemodynamics previous to closure of significant septal 
defects. 
 
The carrier frequency of pathogenic mutations of BMPR-2 has been estimated to be 0.01- 
0.001% in the healthy normal population.(30) This low carrier frequency in the normal 
population makes it obsolete to calculate a statistical significance of several cases of 
mutations in a minor study group like this. Thus, our finding of two independent cases of 
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BMPR-2 mutation among 44 patients probably must be considered important for either 
exercise-induced PAH or congenital cardiac septal defects or for both. The TGF- 
superfamily plays an essential role in cardiac and pulmonary vascular development as well as 
in the pathogenesis of PAH. Consequently, the presence of a congenital cardiac septal defect 
and the presence of secondary PAH may be two different expressions of the same genetically 
determined general vasculopathy. The long-term implications of exercise-induced PAH in 
congenital heart disease are unknown.(27) Genetical changes may increase the risk of 
deterioration into PAH at rest. Thus, genetical analysis in all children with congenital septal 
defects may facilitate that mutation carriers will have their defect closed early in life with 
subsequent life-long medical follow-up. 
 
In conclusion we have shown that genetic changes in TGF- related genes may be 
overrepresented in patients with cardiac septal defects and exercise-induced pulmonary 
hypertension. The mutation Y589C in the BMPR-2 gene has not previously been reported. 
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Tables
 
Table 1: Basic demographics 
 
N Sex
(male/female) 
Age (years) 
Mean±SD1
Height (cm) 
Mean±SD
Weight (kg) 
Mean±SD
BMI2(kg/m2)
Mean±SD
44 19/25 17.5±3.3 167.4±8.8 59.7±11.0 21.3±3.5
 
1 : SD = standard deviation 
2 : BMI = body mass index 
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Table 2--Hemodynamic and genetic results 
 
Patient 
No. Sex
Age 
(years) Diagnose 
Maximal RVSP during 
exercise (mmHg) Mutation / deletion 
1 female 19 untreated VSD 24 -
2 female 19 closed ASD 24 -
3 male 24 closed VSD 24 -
4 female 18 closed ASD 26 -
5 male 15 closed ASD 28 S775N1
6 female 20 closed VSD 28 -
7 female 21 untreated VSD 30 -
8 female 14 untreated VSD 30 -
9 female 15 closed VSD 30 -
10 female 17 untreated VSD 32 -
11 male 14 untreated VSD 32 -
12 female 16 closed ASD 34 -
13 male 15 closed ASD 34 S775N1
14 female 23 closed ASD 34 -
15 female 23 closed ASD 34 -
16 female 16 closed ASD 34 -
17 female 20 closed ASD 36 -
18 male 15 closed VSD 36 -
19 male 19 untreated VSD 36 -
20 female 13 untreated VSD 36 -
21 male 18 closed VSD 36 -
22 male 16 closed ASD 36 -
23 female 17 closed ASD 38 -
24 female 15 closed ASD 39 -
25 female 21 untreated VSD 39 -
26 male 14 untreated VSD 41 -
27 female 17 untreated VSD 41 -
28 female 18 closed ASD 41 -
29 male 16 untreated VSD 41 S775N1
30 male 21 closed ASD 43 -
31 female 13 closed VSD 46 -
32 male 20 closed ASD 46 -
33 female 21 untreated VSD 49 -
34 female 18 closed ASD 49 Y589C2
35 female 16 closed ASD 49 -
36 male 16 untreated VSD 51 -
37 female 24 closed VSD 54 -
38 male 12 untreated VSD 57 -
39 male 15 closed VSD 57 Y589C2
40 male 17 untreated VSD 57 -
41 female 12 closed VSD 61 -
42 male 22 untreated VSD 73 -
43 male 13 closed VSD 73 -
44 male 21 closed VSD 76 -
The patients are sorted in ascending order by maximal RVSP during submaximal exercise. 
1 : Mutation S775N (c. 2324, G>A) in exon 12 of the BMPR-2 gene 
2 : Mutation Y589C (c.1766, A>G) in exon 12 of the BMPR-2 gene 
 
